ModifiedFidelis CarePolicy CP.MP.162

Tandem Transplant (Clinical Policy)

Defines medical necessity criteria, contraindications, and coding implications for planned tandem (sequential/double) hematopoietic cell transplants primarily for multiple myeloma, high‑risk neuroblastoma, and testicular germ cell tumors; applies to Fidelis Care/Centene-affiliated health plans and providers requesting authorization.

Policy Summary

PayerFidelis Care

PolicyTandem Transplant (Clinical Policy)

Policy CodePolicy CP.MP.162

Change TypeContraindications revisedHIV and substance-use criteria added

Effective Date

Next Review Date

Key ActionSubmit prior authorization demonstrating indication, timing within six months, and absence of listed contraindications (include CD4/ART data if HIV-positive).

SourceLink

POLICY UPDATE CHANGES

Updated verbiage for neuroblastoma age-related criteria and other item wording (I.A.3.b., c., d.).

Added a substance use contraindication to the list of contraindications (I.B.15).

Replaced prior broad organ-dysfunction contraindications with a new, enumerated contraindication list (I.B.1 through I.B.6).

Added HIV-specific conditions for consideration (CD4 >200, absence of active AIDS-defining infection, on effective ART).

Replaced broad contraindications ('Inadequate cardiac, renal, pulmonary, or hepatic function and significant, uncorrectable, life-limiting medical condition') with a specific list including GFR thresholds, acute liver failure, acute renal failure, septic shock, active disseminated infection, active tuberculosis, HIV with detectable viral load, progressive cognitive impairment, and other severe uncontrolled medical conditions.

Added substance use contraindication and added specific HIV-related criteria (CD4 >200 cells/mm3, absence of active AIDS-defining opportunistic infection, and on effective ART).

Updated age-related verbiage to reflect months of age instead of days for pediatric criteria.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Initial Tandem Autologous Transplant Criteria

Covered when ALL of the following are met for tandem autologous transplant:

Overall: Member/enrollee meets an accepted diagnosis AND lacks listed contraindications

Accepted diagnoses (I.A): Member/enrollee has one or more of: newly diagnosed or responsive multiple myeloma; testicular germ cell tumors (relapsed or cisplatin‑refractory); high‑risk neuroblastoma defined by specified stage/age/MYCN criteria

See I.A.3.a–d for detailed neuroblastoma stage/age/MYCN combinations

No significant organ dysfunction or severe comorbidities (I.B): Member/enrollee does not have any contraindication such as bilirubin > 2 mg/dL; INR > 1.6 (unless on oral anticoagulants); EF < 45%; FEV1 ≤ 50% predicted; DLCO ≤ 60% predicted; Karnofsky/Lansky < 70% or ECOG > 2

See policy I.B.1–5 for physiologic thresholds

Tandem autologous → allogeneic transplant for Multiple Myeloma

Covered sequences for multiple myeloma when none of the contraindications apply:

Autologous then related allogeneic (II): Tandem autologous transplant followed by an allogeneic transplant from an HLA‑identical sibling donor with reduced‑intensity conditioning is medically necessary for untreated, newly diagnosed MM when contraindications in I.B. are absent

Autologous then unrelated allogeneic (III): Tandem autologous followed by an allogeneic transplant from an HLA‑compatible unrelated donor will be considered on a case‑by‑case basis for untreated, newly diagnosed MM when contraindications in I.B. are absent

Covered with criteria

Coverage criteria and contraindications updated; coverage applies when indications are met and none of the specified contraindications are present.

General coverage condition

Indications: Indication is one of: multiple myeloma, high‑risk neuroblastoma, testicular/germ cell tumors, or other indications supported by cited guidelines
Supported by NCCN, ASBMT, and other references in policy
Contraindications absent: None of the following are present: GFR below acceptable threshold or acute renal failure, acute liver failure, septic shock, active extrapulmonary or disseminated infection, active tuberculosis, HIV with detectable viral load (unless HIV-specific criteria met), progressive cognitive impairment, severe uncontrolled medical condition, active substance use disorder
Policy replaced prior contraindication list with streamlined list

The policy revision removed the prior general exclusion language that stated current evidence does not support tandem transplants for indications beyond those specifically listed. This change narrows the policy text by deleting the former broad statement and clarifies that coverage decisions will be tied to the enumerated indications and updated guideline references rather than an overarching unsupported‑indications declaration.

Patients who meet an accepted indication but who have any of the enumerated contraindications are not eligible for coverage. Examples called out in the revisions include active or disseminated infection, uncontrolled or acute organ failure, detectable HIV viral load (unless HIV‑specific criteria are met), and active substance use; presence of these conditions should be documented and may be grounds for denial.

The prior broad criterion (previously labeled IV) stating that tandem transplants were not supported for indications other than those listed has been removed. The policy text now confines coverage statements to the approved, listed indications (e.g., multiple myeloma, high‑risk neuroblastoma, testicular germ cell tumors) and relies on the updated, itemized contraindication list for exclusion decisions.

A former general statement that evidence did not support tandem transplants for other indications was deleted during revision; the policy now limits coverage to the specific indications enumerated in the criteria and to cases that meet the updated contraindication and eligibility requirements.

Candidate Disease-Specific Criteria

Candidate disease-specific criteria

Disease-specific candidate criteria are enumerated; include disease staging/biologic features and response status where specified.

Multiple Myeloma: Newly diagnosed or responsive MM; candidates should be transplant‑eligible per NCCN guidance (collect stem cells for two transplants when appropriate); consider tandem when VGPR is not achieved after first HCT or for high‑risk features

NCCN recommends collecting enough hematopoietic stem cells for two transplants; tandem may be considered when VGPR not achieved

Testicular germ cell tumors: Relapsed testicular cancer or tumors refractory to a cisplatin‑based regimen; high‑dose chemotherapy with autologous SCT, single or tandem, is an accepted option

Refer to specialized centers and trial evidence

High‑risk neuroblastoma: Children meeting specified INSS/INRG high‑risk criteria (stage/age/MYCN amplification and unfavorable histology combinations) are candidates for tandem ASCT as consolidation; randomized trials showed improved EFS for tandem ASCT

Contraindications

Providers must ensure that documentation clearly addresses the absence or presence of the contraindications listed above. Clinical documentation expectations: include recent laboratory results (bilirubin, INR, creatinine/GFR), up-to-date cardiac testing (MUGA or echocardiogram with EF), pulmonary function testing (FEV1 and DLCO), performance status scores (Karnofsky, Lansky, or ECOG), and infection workup (cultures, TB testing, HIV viral load and CD4 when applicable). If a contraindication is present but potentially correctable, provide documentation of corrective measures and reassessment results.

Provider action: If any contraindication is present, explicitly state whether it is correctable and document interventions and follow-up testing demonstrating resolution or stabilization. For members with HIV, include evidence of effective antiretroviral therapy and (when required by policy updates) CD4 count > 200 cells/mm3 and absence of active AIDS-defining opportunistic infection. For substance use concerns or other unstable medical conditions, provide treatment engagement documentation and evidence of stability prior to transplantation consideration.

Pre-Transplant Evaluation Requirements

Documentation Required

Required pre-transplant evaluation

Pre-transplant evaluation must include objective assessment of organ function (liver tests, cardiac EF by MUGA/echo, pulmonary testing including FEV1 and DLCO), coagulation status (INR), performance status, and infectious disease evaluation prior to approval.

Document liver function (eg, bilirubin), INR, cardiac EF, FEV1 and DLCO values.
Document infectious disease assessment and stem cell collection details per background procedures.

Documentation Required

Document absence of contraindications and HIV parameters

Pre-transplant evaluation submissions must explicitly document absence of the policy-listed contraindications and, when applicable for HIV-positive patients, include HIV control parameters such as CD4 count and antiretroviral therapy status.

When HIV-positive, document CD4 cell count > 200 cells/mm3, absence of active AIDS-defining opportunistic infection, and that the member is on effective ART.
State in the record that none of the contraindications in I.B. are present.

Provider Actions and Documentation

Prior Authorization

Prior authorization required for tandem transplant

Prior authorization is required for tandem transplant and must demonstrate that the indication meets medical necessity criteria, including the accepted diagnosis, timing (planned within six months of the first transplant), and absence of listed contraindications.

Include diagnosis (eg, MM, testicular GCT, high‑risk neuroblastoma) and planned interval (≤ 6 months).
Show evidence that none of the contraindications in section I.B. are present.

Prior Authorization

Prior authorization documentation requirements

Prior authorization submissions should document patient-specific eligibility and explicitly confirm absence of listed contraindications; when relevant for HIV-positive members, include HIV-specific eligibility documentation (CD4 >200, on effective ART, no active AIDS-defining infection).

Provide CD4 count and ART status when applicable.
Include evidence of adequate organ function and performance status per policy thresholds.

Coding and Billing

Referenced procedure codesCPT | HCPCS

38205	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic.
38206	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous.
38230	Bone marrow harvesting for transplantation; allogeneic.
38232	Bone marrow harvesting for transplantation; autologous.
38240	Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor.
38241	Hematopoietic progenitor cell (HPC); autologous transplantation.
S2150	Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre and post-transplant care in the global definition.

inv-10: Bilirubin — Lab threshold relevant to contraindication/denial considerations

Bilirubin threshold> 2 mg/dL

ContextBilirubin > 2 mg/dL is listed as a contraindication to tandem autologous transplant

ActionDocument serum total bilirubin in pre-transplant evaluation; requests may be denied if > 2 mg/dL

inv-11: INR — Lab/coagulation threshold (unless on oral anticoagulants)

INR threshold> 1.6 (unless on oral anticoagulants)

ContextINR > 1.6 is a hemostasis-related contraindication absent therapeutic oral anticoagulation

Center and Operational Expectations

Note

Refer to full policy for center requirements

Center-specific accreditation or operational requirements are not specified in this policy excerpt; providers should refer to the full policy or the payer’s provider manual for any center qualification requirements.

Check the Health Plan/provider manual for transplant center qualifications prior to submission.

Note

Transplants expected in qualified centers

This policy was developed by experienced clinicians and standard practice is that transplants occur in qualified transplant centers per the Health Plan’s procedures and applicable accreditation.

Ensure that planned transplant facility meets Health Plan or accreditation requirements documented elsewhere.

Post-Transplant Coverage and Follow-up

inv-44: Transplant-related hospitalization, follow-up, and associated services — Coding references include inpatient/outpatient global definitions and related service considerations

Primary CPT/HCPCS codes38205, 38206, 38230, 38232, 38240, 38241, S2150

DescriptionS2150 describes global definition including pre/post-transplant care, pheresis, cell storage, hospitalization, and outpatient follow-up

ActionUse these procedure codes when billing for transplant-related hospitalization, follow-up, and associated services per policy guidance

inv-45: Post-transplant follow-up and coverage subject to applicable regulatory and plan rules — Align with Medicare/NCD/LCD and state Medicaid requirements

Regulatory alignmentPost-transplant follow-up and coverage should align with applicable Medicare NCDs/LCDs and state Medicaid rules

Background

A tandem transplant is defined as a planned second course of high‑dose therapy and hematopoietic cell transplant performed within six months of the first to improve depth and duration of response. Peripheral blood hematopoietic stem cells are typically collected during initial mobilization and used for the subsequent transplant; evidence of benefit varies by disease, with some trials showing improved event‑free or progression‑free survival in multiple myeloma and high‑risk neuroblastoma.

Definitions

inv-26: Tandem transplant definition — Planned second course within six months; sequential/double transplant definition

Definition — tandem transplantA planned second course of high-dose therapy and hematopoietic cell transplant within six months of the first

Alternate termsAlso known as sequential or double transplant; prospectively planned (differs from repeat HCT for relapse)

Typical usePerformed to deepen and extend response; second transplant often uses cells collected during initial mobilization

inv-27: Tandem transplant — Two planned sequential hematopoietic stem cell transplants (commonly two autologous or autologous→reduced-intensity allogeneic)

Operational descriptionTwo planned sequential hematopoietic stem cell transplants (commonly two autologous transplants or autologous followed by reduced-intensity allogeneic)

Purpose

Evaluation and Authorization Process

Step Therapy

NCCN guidance on collection and tandem use (authorization visibility)

NCCN guidance recommends collecting stem cells for two transplants when appropriate and considering tandem transplant particularly for patients who do not achieve VGPR after first HCT or who have high‑risk multiple myeloma; include this guideline-based rationale in authorization materials where relevant.

State whether the patient failed to achieve VGPR after first HCT or has high‑risk disease features.

Prior Authorization

Prior authorization required (authorization workflow)

Prior authorization is required and must demonstrate that the indication meets medical necessity (accepted diagnosis, timing within six months, and absence of listed contraindications); include these elements in the authorization request.

Provide diagnosis, planned timing for the second transplant (≤ 6 months), and documentation that contraindications are absent.
When sequencing autologous → allogeneic for MM, include donor type and conditioning intensity as specified in policy.

Policy Summary

PayerFidelis Care

PolicyTandem Transplant (Clinical Policy)

Policy CodePolicy CP.MP.162

Change TypeContraindications revisedHIV and substance-use criteria added

Effective Date

Next Review Date

Key ActionSubmit prior authorization demonstrating indication, timing within six months, and absence of listed contraindications (include CD4/ART data if HIV-positive).

SourceLink

On This Page

Documentation Required

Required clinical documentation for authorization

Clinical documentation must include details of HSC/HPC collection (timing and adequacy), the rationale for a planned tandem transplant (including that the second transplant is planned within six months), and objective evidence of response or disease status supporting the plan.

State that peripheral blood HSCs were collected during initial mobilization and whether collection was sufficient for two transplants.
Provide disease response data and the planned timing for the second transplant (≤ 6 months).

Documentation Required

Document HIV-related eligibility parameters

Policy updates require documentation of HIV-specific clinical criteria when applicable, specifically CD4 > 200 cells/mm3, absence of active AIDS‑defining infections, and that the member is on effective ART; include these parameters in the authorization submission when the patient is HIV-positive.

If HIV-positive, include recent CD4 count, statement regarding active opportunistic infections, and current ART regimen.
Reference the policy’s added HIV-related eligibility criteria in the submission.